350 related articles for article (PubMed ID: 23109727)
61. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
[TBL] [Abstract][Full Text] [Related]
62. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
63. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
Kim MH; Shim KS; Kim SH
Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
[TBL] [Abstract][Full Text] [Related]
64. OA10 is a novel p38alpha mitogen-activated protein kinase inhibitor that suppresses osteoclast differentiation and bone resorption.
Jiang T; Qin A; Shao ZY; Tian B; Zhai ZJ; Li HW; Zhu ZA; Dai KR; Ming HZ; Yu YP; Jiang Q
J Cell Biochem; 2014 May; 115(5):959-66. PubMed ID: 24357524
[TBL] [Abstract][Full Text] [Related]
65. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
[TBL] [Abstract][Full Text] [Related]
66. Orostachys japonicus Suppresses Osteoclast Differentiation by Inhibiting NFATc1 Expression.
Shim KS; Ha H; Kim T; Lee CJ; Ma JY
Am J Chin Med; 2015; 43(5):1013-30. PubMed ID: 26205967
[TBL] [Abstract][Full Text] [Related]
67. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
68. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
[TBL] [Abstract][Full Text] [Related]
69. Adseverin mediates RANKL-induced osteoclastogenesis by regulating NFATc1.
Song MK; Lee ZH; Kim HH
Exp Mol Med; 2015 Dec; 47(12):e199. PubMed ID: 26642432
[TBL] [Abstract][Full Text] [Related]
70. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
71. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
[TBL] [Abstract][Full Text] [Related]
72. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
[TBL] [Abstract][Full Text] [Related]
73. Miconazole inhibits receptor activator of nuclear factor-κB ligand-mediated osteoclast formation and function.
Zheng T; Wang X; Yim M
Eur J Pharmacol; 2014 Aug; 737():185-93. PubMed ID: 24842191
[TBL] [Abstract][Full Text] [Related]
74. Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action.
Kim HJ; Lee Y; Chang EJ; Kim HM; Hong SP; Lee ZH; Ryu J; Kim HH
Mol Pharmacol; 2007 Aug; 72(2):418-28. PubMed ID: 17504945
[TBL] [Abstract][Full Text] [Related]
75. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
Park CK; Lee Y; Chang EJ; Lee MH; Yoon JH; Ryu JH; Kim HH
Biochem Pharmacol; 2008 Jun; 75(11):2175-82. PubMed ID: 18433733
[TBL] [Abstract][Full Text] [Related]
76. The relevance of leukotrienes for bone resorption induced by mechanical loading.
Moura AP; Taddei SR; Queiroz-Junior CM; Madeira MF; Rodrigues LF; Garlet GP; Souza DG; Machado FS; Andrade I; Teixeira MM; Silva TA
Bone; 2014 Dec; 69():133-8. PubMed ID: 25270168
[TBL] [Abstract][Full Text] [Related]
77. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
[TBL] [Abstract][Full Text] [Related]
78. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway.
Ouyang Z; Zhai Z; Li H; Liu X; Qu X; Li X; Fan Q; Tang T; Qin A; Dai K
Biochem Pharmacol; 2014 Aug; 90(3):276-87. PubMed ID: 24950468
[TBL] [Abstract][Full Text] [Related]
79. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
80. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
Kim K; Kim JH; Youn BU; Jin HM; Kim N
J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
